PTC's oral SMA candidate improves motor development scores in pivotal trial

PTC Therapeutics Inc. (NASDAQ:PTCT) reported updated interim data from part 1 of the pivotal Phase II/III FIREFISH trial showing that oral risdiplam (RG7916) improved motor development scores in infants with spinal muscular atrophy (SMA) type 1.

In 11 evaluable patients in part 1, risdiplam increased Children's Hospital of Philadelphia Infant

Read the full 495 word article

User Sign In